Resolvin-based therapy to help pancreatic cancer patients
Official title: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer
Funded at Thetis Pharmaceuticals, LLC · NIH-11411491 · Data updated 2026-11-12
A new therapy called TP-317 uses a natural anti-inflammatory molecule to help the body clear debris, boost anti-tumor immunity, and work with chemotherapy to slow pancreatic cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thetis Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Deep River, United States) |
| Project start | June 2, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $271,378 |
| NIH project number | 5R44CA278026-03 |
| Project ID | NIH-11411491 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic cancer could be eligible in future clinical development stages after preclinical success and IND submission.
✕Less likely to help
People with pancreatic cancer would not benefit until the therapy advances to human trials and shows safety and effectiveness.
What this research studies
This project develops TP-317, a Resolvin E1–based treatment, to target the inflammatory environment and cell debris that support pancreatic cancer growth. It builds on nonclinical work showing the therapy can reduce tumor size in animals and may work alongside chemotherapy. The team aims to complete key preclinical studies to support an IND application so that future patients could access a potentially safer and more effective option. If successful, TP-317 could shift how pancreatic cancer is treated and improve survival odds for patients.
Why it matters
Potential benefit: If successful, this therapy could become part of the treatment options for pancreatic cancer, potentially improving survival and reducing treatment-related toxicity.
How similar studies have gone: Preclinical work suggests TP-317 can suppress tumor growth in animals and enhance chemotherapy effects, supporting progression toward human trials.
Where this research is happening
-
Thetis Pharmaceuticals, LLC
Deep River, United States Active
Researchers
- Principal investigator: Parkinson, John — Thetis Pharmaceuticals, LLC
- Study coordinator: Parkinson, John
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.